Related Experiment Videos
Generalized pustular psoriasis. A review of 63 cases
1Department of Dermatology, Mayo Clinic, Rochester, Minn. 55905.
Archives of Dermatology
|September 1, 1991
Summary
Generalized pustular psoriasis (GPP) classification aids treatment. Subgrouping GPP patients improves understanding of disease variability and guides therapeutic choices for better patient outcomes.
Area of Science:
- Dermatology
- Clinical Medicine
Background:
- A 29-year retrospective study analyzed 63 hospitalized patients with generalized pustular psoriasis (GPP).
- Patients were categorized into four subgroups: acute (von Zumbusch), subacute annular, chronic (acral), and mixed, based on disease onset and morphology.
- This classification aims to enhance understanding of GPP's diverse presentations.
Purpose of the Study:
- To classify generalized pustular psoriasis (GPP) patients into distinct subgroups.
- To improve the understanding of GPP variability.
- To aid in selecting appropriate treatment strategies for different GPP presentations.
Main Methods:
- Retrospective analysis of 63 hospitalized patients diagnosed with generalized pustular psoriasis (GPP) over 29 years.
- Classification of patients into four subgroups: acute (von Zumbusch), subacute annular, chronic (acral), and mixed.
- Analysis of patient demographics, disease characteristics, precipitating factors, complications, and hospitalization duration.
Main Results:
- The average age of onset for GPP was 50 years, with equal male and female distribution.
- Localized infections precipitated flares in 11 patients; approximately 25% experienced complications, primarily superinfections.
- Average hospitalization was 30 days, with hypocalcemia, female sex, and prior psoriasis history correlating with longer stays.
Conclusions:
- Topical therapies showed some benefit, but systemic medications were frequently required for GPP management.
- Coal tar, ultraviolet light (UVL), and psoralen-ultraviolet A (PUVA) may be effective treatments.
- Caution is advised with UVL and PUVA therapies as they can potentially exacerbate GPP.